BR9915027B1 - derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, medicamento contendo tais compostos, processo de preparação do mesmo, e aplicação dos mesmos. - Google Patents

derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, medicamento contendo tais compostos, processo de preparação do mesmo, e aplicação dos mesmos.

Info

Publication number
BR9915027B1
BR9915027B1 BRPI9915027-1A BR9915027A BR9915027B1 BR 9915027 B1 BR9915027 B1 BR 9915027B1 BR 9915027 A BR9915027 A BR 9915027A BR 9915027 B1 BR9915027 B1 BR 9915027B1
Authority
BR
Brazil
Prior art keywords
pyridin
ylamino
diaryl
substituted
preparing
Prior art date
Application number
BRPI9915027-1A
Other languages
English (en)
Other versions
BR9915027A (pt
Inventor
Reinhard Kirsch
Alfons Enhsen
Heiner Glombik
Werner Kramer
Eugen Falk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR9915027A publication Critical patent/BR9915027A/pt
Publication of BR9915027B1 publication Critical patent/BR9915027B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
BRPI9915027-1A 1998-10-02 1999-09-18 derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, medicamento contendo tais compostos, processo de preparação do mesmo, e aplicação dos mesmos. BR9915027B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19845406A DE19845406C2 (de) 1998-10-02 1998-10-02 Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP1999/006933 WO2000020393A1 (de) 1998-10-02 1999-09-18 Substituierte 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (2)

Publication Number Publication Date
BR9915027A BR9915027A (pt) 2001-07-17
BR9915027B1 true BR9915027B1 (pt) 2010-09-08

Family

ID=7883187

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9915027-1A BR9915027B1 (pt) 1998-10-02 1999-09-18 derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, medicamento contendo tais compostos, processo de preparação do mesmo, e aplicação dos mesmos.

Country Status (23)

Country Link
US (1) US6596728B1 (pt)
EP (1) EP1117642B1 (pt)
JP (1) JP4544746B2 (pt)
KR (1) KR100609255B1 (pt)
CN (1) CN1173951C (pt)
AR (1) AR021845A1 (pt)
AT (1) ATE267809T1 (pt)
AU (1) AU757689B2 (pt)
BR (1) BR9915027B1 (pt)
CA (1) CA2345985C (pt)
CZ (1) CZ299569B6 (pt)
DE (2) DE19845406C2 (pt)
DK (1) DK1117642T3 (pt)
ES (1) ES2219066T3 (pt)
HK (1) HK1051533A1 (pt)
HU (1) HU226688B1 (pt)
ID (1) ID29249A (pt)
PL (1) PL205034B1 (pt)
PT (1) PT1117642E (pt)
RU (1) RU2224748C2 (pt)
TR (1) TR200100896T2 (pt)
WO (1) WO2000020393A1 (pt)
ZA (1) ZA200102587B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030063462A (ko) * 2000-12-21 2003-07-28 아벤티스 파마 도이칠란트 게엠베하 디페닐 아제티디논 유도체, 이의 제조 방법, 이들화합물을 함유하는 약제 및 이의 용도
KR20040027963A (ko) * 2001-08-22 2004-04-01 아벤티스 파마 도이칠란트 게엠베하 아릴 치환된 프로판올아민 유도체와 다른 활성 성분과의배합 제제 및 이의 용도
US7161008B2 (en) * 2002-05-03 2007-01-09 Sanofi - Aventis Deutschland GmbH Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them
DE10219987A1 (de) * 2002-05-03 2004-04-08 Aventis Pharma Deutschland Gmbh Optisch aktive β-Aminoketone, optisch aktive 1,3-Aminoalkohole und Verfahren zu deren Herstellung
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
AU2004283751B2 (en) * 2003-10-24 2011-05-19 Exelixis, Inc. p70S6 kinase modulators and method of use
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
DK2771003T3 (en) 2011-10-28 2017-07-17 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver disease
SG10201903512SA (en) 2011-10-28 2019-05-30 Lumena Pharmaceuticals Inc Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
JP2016514684A (ja) 2013-03-15 2016-05-23 ルメナ ファーマシューティカルズ エルエルシー 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤
CA2907214A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
JP2022520121A (ja) 2019-02-12 2022-03-28 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞を治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000816A1 (en) * 1977-08-06 1979-02-21 Beecham Group Plc Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them
DK0869121T3 (da) 1997-04-04 2004-09-20 Aventis Pharma Gmbh Hypolipidæmiske propanolaminderivater
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung

Also Published As

Publication number Publication date
HU226688B1 (hu) 2009-06-29
KR20010075496A (ko) 2001-08-09
WO2000020393A1 (de) 2000-04-13
DE19845406C2 (de) 2001-10-18
RU2224748C2 (ru) 2004-02-27
ATE267809T1 (de) 2004-06-15
DK1117642T3 (da) 2004-08-09
AU757689B2 (en) 2003-03-06
CZ20011152A3 (cs) 2001-07-11
HUP0103533A2 (hu) 2002-02-28
CA2345985C (en) 2010-06-29
AR021845A1 (es) 2002-08-07
JP2002526530A (ja) 2002-08-20
CN1173951C (zh) 2004-11-03
ZA200102587B (en) 2001-11-05
AU6192699A (en) 2000-04-26
HUP0103533A3 (en) 2003-01-28
US6596728B1 (en) 2003-07-22
PL205034B1 (pl) 2010-03-31
BR9915027A (pt) 2001-07-17
KR100609255B1 (ko) 2006-08-04
CA2345985A1 (en) 2000-04-13
PT1117642E (pt) 2004-09-30
DE19845406A1 (de) 2000-04-13
ID29249A (id) 2001-08-16
HK1051533A1 (en) 2003-08-08
PL347096A1 (en) 2002-03-25
TR200100896T2 (tr) 2001-09-21
ES2219066T3 (es) 2004-11-16
CZ299569B6 (cs) 2008-09-03
EP1117642A1 (de) 2001-07-25
DE59909606D1 (de) 2004-07-01
EP1117642B1 (de) 2004-05-26
CN1391558A (zh) 2003-01-15
JP4544746B2 (ja) 2010-09-15

Similar Documents

Publication Publication Date Title
BR9814340B1 (pt) compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
FR13C0008I2 (fr) Derives de phosphonocephem, leur procede de preparation et leur utilisation
CY2369B1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same.
HUP0001539A3 (en) 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
ATE318138T1 (de) Pharmazeutisches mittel zur behandlung von diabetes
EE200000707A (et) Oksasolidinooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
PT955995E (pt) Utilizacao de complexos para a preparacao de composicoes de tratamento para peles sensiveis, processo de preparacao e compisicoes hipoalergenicas
BR8906833A (pt) Composicao,processo para preparacao de compostos e aplicacao dos mesmos
MA24800A1 (fr) Agent de blanchiment et son procede de preparation
BR9000289A (pt) Compostos,processo de preparacao dos mesmos e composicao de polimero organico estabilizado
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
BR9100046A (pt) Derivados de azaoxindole,composicao farmaceutica e processo para o tratamento de mamiferos
BR9915027B1 (pt) derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, medicamento contendo tais compostos, processo de preparação do mesmo, e aplicação dos mesmos.
EE9800426A (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
NO20006257L (no) Artemisininderivater, fremgangsmåte ved fremstilling derav samt farmasöytiske sammensetninger inneholdende slike
EE200000651A (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
HUP0003148A3 (en) Cyanoguanidine derivatives, process for producing them and pharmaceutical compositions containing them
NO20001288D0 (no) Substituerte 1,2,3,4,5,6-heksahydro-2,6-metano-3-benzazocin- 10-oler, fremgangsmÕte for fremstilling derav og anvendelse som legemiddel
EP0408946A3 (en) Method and apparatus for sterilising, disinfecting and/or drying
EE9800264A (et) Taksoidid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
HUP0003150A2 (en) Cyanoguanidine derivatives, process for producing them and pharmaceutical compositions containing them
HUP0003829A2 (en) Cyanoguanidine derivatives, process for producing them and pharmaceutical compositions containing them
NO990675D0 (no) 11-acetyl-12,13-dioksabisyklo[8.2.1.]-tridekenonderivater, fremgangsmÕter for deres fremstilling, samt legemidler inneholdende slike forbindelser
BR9914250B1 (pt) compostos de bifenila substituìdos por cánfora ou derivados de hidantoìna, processo de preparação dos referidos compostos, formulação cosmética contendo os mesmos e uso não terapêutico relacionado.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: REFERENTE A RPI 1865 DE 03/10/2006 COD. (25.1), POR TER SIDO INDEVIDO.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 401/12, C07D 401/14, C07D 409/14, C07D 405/14, C07D 417/14, C07D 471/01, C07D 473/08, C07D 473/34, C07D 413/14, A61K 31/44, A61K 31/513, A61K 31/437, A61K 31/52, A61K 31/522, A61P 3/06, A61P 9/10

Ipc: C07D 401/12 (2009.01), C07D 401/14 (2009.01), C07D

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.